127 related articles for article (PubMed ID: 20406967)
1. Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice.
Soudja SM; Wehbe M; Mas A; Chasson L; de Tenbossche CP; Huijbers I; Van den Eynde B; Schmitt-Verhulst AM
Cancer Res; 2010 May; 70(9):3515-25. PubMed ID: 20406967
[TBL] [Abstract][Full Text] [Related]
2. An inducible mouse model of melanoma expressing a defined tumor antigen.
Huijbers IJ; Krimpenfort P; Chomez P; van der Valk MA; Song JY; Inderberg-Suso EM; Schmitt-Verhulst AM; Berns A; Van den Eynde BJ
Cancer Res; 2006 Mar; 66(6):3278-86. PubMed ID: 16540681
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
4. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background.
Ackermann J; Frutschi M; Kaloulis K; McKee T; Trumpp A; Beermann F
Cancer Res; 2005 May; 65(10):4005-11. PubMed ID: 15899789
[TBL] [Abstract][Full Text] [Related]
5. Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes.
Itoh T; Storkus WJ; Gorelik E; Lotze MT
J Immunol; 1994 Aug; 153(3):1202-15. PubMed ID: 7517974
[TBL] [Abstract][Full Text] [Related]
6. In vivo assessment of RAS-dependent maintenance of tumor angiogenesis by real-time magnetic resonance imaging.
Tang Y; Kim M; Carrasco D; Kung AL; Chin L; Weissleder R
Cancer Res; 2005 Sep; 65(18):8324-30. PubMed ID: 16166309
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
8. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?
Auphan-Anezin N; Verdeil G; Grange M; Soudja SM; Wehbe M; Buferne M; Mas A; Schmitt-Verhulst AM
Pigment Cell Melanoma Res; 2013 Mar; 26(2):167-75. PubMed ID: 23217139
[TBL] [Abstract][Full Text] [Related]
10. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
11. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
[TBL] [Abstract][Full Text] [Related]
12. Induction of nevi and skin tumors in Ink4a/Arf Xpa knockout mice by neonatal, intermittent, or chronic UVB exposures.
van Schanke A; van Venrooij GM; Jongsma MJ; Banus HA; Mullenders LH; van Kranen HJ; de Gruijl FR
Cancer Res; 2006 Mar; 66(5):2608-15. PubMed ID: 16510579
[TBL] [Abstract][Full Text] [Related]
13. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.
Zatloukal K; Schneeberger A; Berger M; Schmidt W; Koszik F; Kutil R; Cotten M; Wagner E; Buschle M; Maass G
J Immunol; 1995 Apr; 154(7):3406-19. PubMed ID: 7897222
[TBL] [Abstract][Full Text] [Related]
14. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
Steitz J; Brück J; Lenz J; Knop J; Tüting T
Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
[TBL] [Abstract][Full Text] [Related]
15. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
16. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
17. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen.
Bai XF; Gao JX; Liu J; Wen J; Zheng P; Liu Y
Cancer Res; 2001 Sep; 61(18):6860-7. PubMed ID: 11559562
[TBL] [Abstract][Full Text] [Related]
18. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
[TBL] [Abstract][Full Text] [Related]
19. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
[TBL] [Abstract][Full Text] [Related]
20. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
